If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

Generation Bio Co. (GBIO)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are an innovative genetic medicines company creating a new class of gene therapy utilizing their proprietary non-viral gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases. Their non-viral gene therapy platform incorporates their high-capacity DNA construct called closed-ended DNA, or ceDNA; their cell-targeted lipid nanoparticle delivery system, or ctLNP; and their established, scalable capsid-free manufacturing process. Using their approach, they are developing novel gene therapies to provide targeted delivery of genetic payloads that include large and multiple genes to a range of tissues across a broad array of diseases. They are also engineering their gene therapies to be redosable, which may enable individualized patient titration to reach the desired level of therapeutic expression and to maintain efficacy throughout a patient’s life. While they are currently a preclinical stage company and have not yet identified a product candidate, they believe that their new class of gene therapy has the potential to reach previously untreatable or under-treated patients and address new indications, including those with large patient populations, thereby unlocking the full potential of genetic medicine.
Geoff McDonough Stephen DiPalma
Employees Founded
85 2016


Address: 301 Binney Street, Cambridge, MA 02142, US

Telephone: (617) 655-7500

Web page:

IPO information

Expected Date 6/12/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $16.00-$18.00
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $848
Revenues (MM) $0
Net Income (Loss) (MM) $-64.9


What do you think will happen with the GBIO share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 7.4
Shares Revised (MM) 10.5
Expected offer amount (MM) $125.8
Realized offer amount(MM) $199.5
JP Morgan/ Jefferies/ Cowen
Wedbush PacGrow

Sector: Healthcare

Tweets about $GBIO

Tweets volume:

RT volume:


Google Trends Stats